
Sumgen Biotech
时迈药业
Sumgen Biotech
Biotech/Healthcare
Shimai Pharmaceuticals is an innovative developer of antibody therapeutics for cancer and immune diseases. Its business model centers on wholly novel drugs and combines end-product development with interim-stage asset transfers and technology-platform licensing.
Latest round: Series C (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-02-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.